Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omecamtiv mecarbil - Amgen/Cytokinetics

Drug Profile

Omecamtiv mecarbil - Amgen/Cytokinetics

Alternative Names: AMG-423; CK-1827452; CK-452

Latest Information Update: 17 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics; Servier
  • Class Esters; Heart failure therapies; Organic chemicals; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure; Heart failure
  • Phase II Acute heart failure
  • No development reported Angina pectoris; Cardiomyopathies

Most Recent Events

  • 16 Jul 2019 Cytokinetics completes enrolment in the GALACTIC-HF phase III trial for Chronic heart failure in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine and United Kingdom (NCT02929329)
  • 18 Mar 2019 Updated efficacy and pharmacodynamics data from the phase II COSMIC-HF trial in Chronic heart failure presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC-2019)
  • 16 Mar 2019 Interim efficacy and adverse event data from a phase II trial in heart faliure presented at the 68th Annual Scientific Session of the American College of Cardiology (ACC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top